Business Wire

ANT-GROUP

20.5.2021 09:39:09 CEST | Business Wire | Press release

Share
Ant Group Publishes its 2020 Sustainability Report: Building a Better World Together

Ant Group today released its 2020 Sustainability Report, highlighting its key activities, achievements and progress in bringing inclusive development and environmental sustainability to the world through digital technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005402/en/

In 2020, Covid-19 transformed the way people live and work. The report outlines Ant’s efforts to support Small and Micro Enterprises (SMEs) in their pandemic recovery, strengthen financial inclusion, bridge digital inequality, and promote sustainability.

“Ant Group remains committed to its mission of using technology to provide ordinary people and small businesses with more equal access to financial and daily life services,” said Ant Group’s Chairman and Chief Executive Officer Eric Jing. “As we face the challenges of today, we feel an even greater sense of responsibility and will strive to explore better solutions to serve the development of society.”

Working with its partners, Ant Group is continuing to build a future that is more inclusive, green, and sustainable, by reducing financing costs for SMEs and micro businesses and developing rural economies, investing in green technologies, and working to further protect the interests of consumers.

Key highlights from the 2020 Sustainability Report are enclosed below.

Supporting Small and Micro Enterprises

In 2020, MYbank, a leading online private commercial bank and an associate of Ant Group, served 35 million SMEs and individually-owned businesses, of which 80% were first-time borrowers of any business loans, while keeping the default rate at a low level.

MYbank’s initiatives to support SMEs’ pandemic recovery included:

  • Providing low-interest and interest-free loans to 8.5 million digital shops and small stores in Hubei Province.
  • Issuing RMB 10 billion in interest-free loan vouchers to businesses in 81 Chinese cities to support the recovery of small shops.
  • Offering a free "zero-billing period" on advance payment services to e-commerce businesses, providing advance payments of more than RMB 200 billion

Adopting and Encouraging Green Initiatives

  • In 2021, Ant announced its carbon neutrality goals and corresponding action plans, pledging to achieve carbon neutrality by 2030.
  • The company also put forward a series of intermediary goals, including a 30% reduction in absolute emissions in Scope 1 and Scope 2 by 2025 (compared with 2020), a full assessment of its supply chain emissions, and a full transition to renewable energy for its leased data center services. Ant Forest, a tree-planting mini program in the Alipay app where users earn points for making low-carbon lifestyle choices, attracted over 550 million users to plant more than 220 million real trees, helping reduce carbon emissions by more than 12 million tons as of December 2020.

Creating Opportunities for Women

  • Launched in late 2019, Ant’s A-Idol Initiative brought employment opportunities to women in less-developed areas, with women accounting for at least 60% of the employees of social enterprises incubated by the initiative.
  • As part of its "Wind Rider” project, Ant funded 40 women’s football teams in rural schools to provide women with more opportunities for education and personal development through football.
  • On July 15, 2020, Ant launched the "Cyber Mulan" program, which aims to assist 50 million women globally within five years, enhancing women's participation and competitiveness in the digital economy.

Access the full report here: https://www.antgroup.com/en/news-media/media-library?type=Sustainability%20Report

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. Ant Group strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye